作者
Tobias Rheude,Giuliano Costa,Flavio Ribichini,Thomas Pilgrim,Ignacio J. Amat‐Santos,Ole De Backer,Won‐Keun Kim,Henrique Barbosa Ribeiro,Francesco Saia,Matjaž Bunc,Didier Tchétché,Philippe Garot,Darren Mylotte,Francesco Burzotta,Yusuke Watanabe,Francesco Bedogni,Tullio Tesorio,Marco Tocci,Anna Franzone,Roberto Valvo,Mikko Savontaus,Hendrik Wienemann,Italo Porto,Caterina Gandolfo,Alessandro Iadanza,Gennaro Santoro,Markus Mach,Azeem Latib,Luigi Biasco,Maurizio Taramasso,Marco Zimarino,Daijiro Tomii,Philippe Nuyens,Lars Søndergaard,Sérgio F. Câmara,Tullio Palmerini,Mateusz Orzałkiewicz,Klemen Steblovnik,Bastien Degrelle,Alexandre Gautier,Paolo Alberto Del Sole,Andrea Mainardi,Michele Pighi,Mattia Lunardi,Hideyuki Kawashima,Enrico Criscione,Vincenzo Cesario,Fausto Biancari,Federico Zanin,Giovanni Esposito,Matti Adam,Eberhard Grube,Stephan Baldus,Vincenzo De Marzo,Elisa Piredda,Stefano Cannata,Fortunato Iacovelli,Martin Andreas,Valentina Frittitta,Elena Dipietro,Claudia Reddavid,Orazio Strazzieri,Silvia Motta,Domenico Angellotti,Carmelo Sgroi,Erion Xhepa,Faraj Kargoli,Corrado Tamburino,Michael Joner,Marco Barbanti
摘要
The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown.We sought to compare different PCI timing strategies in TAVI patients.The REVASC-TAVI registry is an international registry including patients undergoing TAVI with significant, stable coronary artery disease (CAD) at preprocedural workup. In this analysis, patients scheduled to undergo PCI before, after or concomitantly with TAVI were included. The main endpoints were all-cause death and a composite of all-cause death, stroke, myocardial infarction (MI) or rehospitalisation for congestive heart failure (CHF) at 2 years. Outcomes were adjusted using the inverse probability treatment weighting (IPTW) method.A total of 1,603 patients were included. PCI was performed before, after or concomitantly with TAVI in 65.6% (n=1,052), 9.8% (n=157) or 24.6% (n=394), respectively. At 2 years, all-cause death was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (6.8% vs 20.1% vs 20.6%; p<0.001). Likewise, the composite endpoint was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (17.4% vs 30.4% vs 30.0%; p=0.003). Results were confirmed at landmark analyses considering events from 0 to 30 days and from 31 to 720 days.In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials.